Perspectum Lands Top Spot in Alantra Pharma Fast 50 Rankings. Read more

Our latest news

We are proud to be leading the way in providing more patient-centric solutions for people with liver disease that helps them and their physician make informed decisions about their care.

Read our latest news to find out more about how we are helping to improve the understanding of liver disease.

Perspectum Lands Top Spot in Alantra Pharma Fast 50 Rankings Posted: March 1, 2021

Awards

New research demonstrates superior performance of LiverMultiScan® for identifying patients with NASH and fibrosis Posted: February 24, 2021

NASH NAFLD LiverMultiScan Liver Disease New publication

LiverMultiScan® could be an alternative to liver biopsy for NASH clinical trials. Posted: February 4, 2021

NAFLD NASH LiverMultiScan New publication ClinicalTrials

UVA Health First Hospital in the State to Offer LiverMultiScan for Non-Invasive Assessment of Liver Disease Posted: February 2, 2021

Perspectum launches study to improve outcomes for patients with liver cancer Posted: January 14, 2021

New grant liver cancer Genetics Radiology Pathology

World’s First Integrated Imaging Service for Long Covid approved by UK’s MHRA Posted: January 14, 2021

Perspectum Announces American Medical Association Issues Unique Category III CPT® Codes for LiverMultiScan Quantitative Multiparametric MR Posted: January 4, 2021

FDA awards funding to Perspectum and physicians at Massachusetts General Hospital to accelerate development of imaging biomarkers as drug development tools in liver disease Posted: December 14, 2020

Perspectum’s RADIcAL1 trial - addressing the health economic burden of invasive diagnostics for NAFLD and NASH Posted: December 9, 2020

RADIcAL NAFLD NASH LiverMultiScan Liver Disease New publication